Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | PTGES | O14684 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | GALK1 | P51570 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.59 |
| ▸ | DUSP4 | Q13115 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14132600 | 0.88 | MAPT (0.60) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL12892076 | 0.84 | MEN1 (0.61) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL14132635 | 0.83 | PTGES (0.67) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL13345210 | 0.81 | PLK1 (0.65) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL14133357 | 0.81 | MEN1 (0.60) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL14133409 | 0.81 | DUSP3 (0.67) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL14132901 | 0.79 | PLK1 (0.62) | MAPTMAPK1MEN1KMT2AMCL1 | |
| SCHEMBL22259725 | 0.77 | PTGES (1.00) | PTGESPTP4A3DUSP4PTP4A1 | |
| SCHEMBL14132896 | 0.77 | SIRT2 (0.63) | MAPTMEN1KMT2ANPSR1LMNA | |
| SCHEMBL14133119 | 0.77 | LMNA (0.58) | MAPTMAPK1MEN1KMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | MAPT 2885/4885MAPK1 557/4885MEN1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.